| Literature DB >> 18268924 |
Marc Licker1, Alexandre Schweizer, Christoph Ellenberger, Jean-Marie Tschopp, John Diaper, François Clergue.
Abstract
Chronic obstructive pulmonary disease (COPD) and heart diseases are considered independent risk factors for mortality and major cardiopulmonary complications after surgery. Coronary artery disease, heart failure and COPD share common risk factors and are often encountered,--isolated or combined--, in many surgical candidates. Perioperative optimization of these high-risk patients deserves a thorough understanding of the patient cardiopulmonary diseases as well as the respiratory consequences of surgery and anesthesia. In contrast with cardiac risk stratification where the extent of heart disease largely influences postoperative cardiac outcome, surgical-related factors (ie, upper abdominal and intra-thoracic procedures, duration of anesthesia, presence of a nasogastric tube) largely dominate patient's comorbidities as risk factors for postoperative pulmonary complications. Although most COPD patients tolerate tracheal intubation under "smooth" anesthetic induction without serious adverse effects, regional anesthetic blockade and application of laryngeal masks or non-invasive positive pressure ventilation should be considered whenever possible, in order to provide optimal pain control and to prevent upper airway injuries as well as lung baro-volotrauma. Minimally-invasive procedures and modern multimodal analgesic regimen are helpful to minimize the surgical stress response, to speed up the physiological recovery process and to shorten the hospital stay. Reflex-induced bronchoconstriction and hyperdynamic inflation during mechanical ventilation could be prevented by using bronchodilating volatile anesthetics and adjusting the ventilatory settings with long expiration times. Intraoperatively, the depth of anesthesia, the circulatory volume and neuromuscular blockade should be assessed with modem physiological monitoring tools to titrate the administration of anesthetic agents, fluids and myorelaxant drugs. The recovery of postoperative lung volume can be facilitated by patient's education and empowerment, lung recruitment maneuvers, non-invasive pressure support ventilation and early ambulation.Entities:
Mesh:
Year: 2007 PMID: 18268924 PMCID: PMC2699974
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Grading of postoperative cardiopulmonary complications
| ECG, treatment with electrolytes, drugs and/or electrical shock | SVE, benign VE, sinus tachycardia, AF + electrolytes adjustment | + pharmacological treatment (anti-arrhythmic) | tachyarrhythmia + electrical shock | cardiac arrest + defibrillation and/or resuscitative maneuvers | |
| ECG, treatment with pacemaker | AV 1st–2nd degree block | AV 2nd degree block (Wenckeback) | AV 3rd degree block + pacemaker | ||
| Chest X-rays, drugs, echocardiography, ICU/HDU transfer, assist device | asymptomatic | + diuretics, vasodilators | + transfer in HDU or ICU,inotropes | low cardiac output syndrome, aortic balloon counterpulsation | |
| echocardiography, drainage | pericardial drainage | low cardiac output and drainage | |||
| ECG, troponin | Transient ECG changes: ST-segment, T wave | Troponin 0.1–1.5 ng/ml | Troponin > 1.5 ng | Troponin > 1.5 ng, unstable angina, arrhythmias, low cardiac output | |
| Chest-X rays, CT-scan, treatment | + chest physiotherapy | + CPAP | + bronchial fibroscopy | ||
| Temperature, WBC count,bacteriology, treatment | + antibiotics, on the ward | + antibiotics and supportive respiratory treatment | + respiratory failure | ||
| SpO2, PaO2, A-aDO2, PaO2/FIO2, chest X-rays treatment | + oxygen therapy | + oxygen therapy | PaO2/FIO2 < 220 + NIV ALI/ARDS | PaO2/FIO2 < 220 + intubation, mechanical ventila tion, ALI/ARDS | |
| Need for ventilatory support | + NIV | intubation, mechanical ventilation | |||
| bronchoscopy, treatment | + endoscopic treatment | + surgical closure, empyema | |||
| chest X-rays, drainage | mild | + thoracic drainage | |||
Abbreviations: SVE, supraventricular extrasystole; VE, ventricular extrasystole; AF, atrial fibrillation; AV, atrioventricular; HDU, high dependency unit; ICU, intensive care unit; ALI, acute lung injury; ARDS, adult respiratory distress syndrome.
Adapted from Dindo D, Clavien PA. 2004.
Multivariate risk indices for postoperative pneumonia, respiratory failure and cardiac complications
| Surgery type/site | ||||
| AAA repair | 6.9 (2.7–17.4) | 15 | 27 | 2.8 (1.6–4.9) |
| Thoracic | 4.2 (2.9–6.2) | 14 | 21 | 2.8 (1.6–4.9) |
| Neurosurgery | 2.5 (1.8–3.5) | 8 | 14 | |
| Upper abdominal | 2.9 (2.3–3.6) | 10 | 14 | 2.8 (1.6–4.9) |
| Vascular | 2.2 (1.8–2.7) | 3 | 14 | 2.8 (1.6–4.9) |
| Head and neck | 1.5 (1.3–1.7) | 8 | 11 | |
| Emergency surgery | 2.2 (1.6–3.1) | 3 | 11 | |
| Prolonged surgery | 2.3 (1.4–3.5) | |||
| General anesthesia | 1.8 (1.4–2.5) | 4 | ||
| Transfusion > 4 units | 4 | |||
| Age 60–69 | 2.1 (1.6–2.6) | |||
| Age 70–79 | 3.0 (2.1–4.4) | 13 | 6 | |
| Age > 80 | 17 | NA | ||
| COPD | 1.8 (1.4–2.2) | 5 | 6 | |
| Coronary artery disease | na | na | 2.4 (1.3–4.2) | |
| History of cardiac failure | 2.9 (1.0–8.0) | na | na | 1.9 (1.1–3.5) |
| History of stroke/TIA | 4 | 3.2 (1.3–6.0) | ||
| Renal insufficiency | 3 | 8 | 3.0 (1.4–6.8) | |
| ASA ≥ 3 | 2.6 (1.7–3.8) | |||
| Functional dependency | 10 | 7 | ||
| Weight loss > 10% | 7 | na | ||
| Altered sensorium | 4 | |||
| Smoking (<1 yr) | 1.3 (1.0–1.6) | 3 | ||
| Steroid treatment | 3 | |||
| Alcohol (≥2 drinks) | 2 | |||
| Albumin <3 g/dL | 2.5 | NA | 9 | |
| 10–15 for pneumonia | 0.24% | |||
| ≤10 for resp. failure | 0.50% | |||
| 16–25 for pneumonia | 1.19% | |||
| 11–19 for resp. failure | 2.10% | |||
| 26–40 for pneumonia | 4.0% | |||
| 20–27 for resp. failure | 5.3% | |||
| 41–55 for pneumonia | 9.4% | |||
| 28–40 for resp. failure | 11.9% | |||
| ≥55 for pneumonia | 15.8% | |||
| ≥40 for resp. failure | 30.9% | |||
BUN >30 mg/dl (respiratory failure or pneumonia), creatinine >2 mg/dl (cardiac complications).
Abbreviations: AAA, aortic abdominal aneurysm; TIA, transient ischemic attack.
Adapted from Arozullah AM et al 2000, Arozullah AM et al 2001, Boersma E et al 2005, Lee TH et al 1999.
General health status assessment
| ASA | Normal healthy, without organic physiologic, or psychiatric disorders | Controlled medical condition without systemic effects (smoking without COPD, anemia, >70 years | Medical condition with systemic effects and/or functional compromise (stable angina or heart failure, moderate BPCO) | Poorly controlled-medical condition potentially life-threatening (eg, unstable angina, severe COPD) | Moribund, expected to survive less than 24 hr postoperatively |
| Duke Activity Status Index | >8 MET run, swim, play tennis | 5–7 MET yardwork, climb 4 flights of stairs | 2–4 MET Light housework, <3 flights of stairs | <2 MET walking 1–2 blocks, climb 1–2 flights of stairs, bedbound |
Abbreviation: MET, metabolic equivalent (1 MET = basal oxygen cons umption).
Figure 1Thoracic wall and diaphragmatic motion during breathing in awake (dotted line) and in anesthetized subjects (continuous line).
Effects of anesthesia on respiratory function
| 1. Lung volume |
| Atelectasis in dependent lung areas |
| ↙ Functional respiratory capacity (FRC) |
| ↗ Closing volume |
| ↙ Lung compliance |
| In COPD patients: ↗ FRC and ↗ dead space (air trapping) due to incomplete expiratory emptying of the most diseased lung regions |
| 2. Airways |
| Bronchodilatation (volatile anesthetic agents) |
| ↙ Tonic activity of the muscle controlling the upper airways |
| ↙ Bronchial mucociliary clearance |
| ↗ = Airway resistance |
| 3. Ventilatory control |
| ↙ Ventilatory response to hypercarbia |
| ↙ Ventilatory response to hypoxia |
| ↙ Ventilatory response to acidosis |
| 4. Pulmonary circulation |
| ↙ Hypoxic vasoconstrictor response (volatile anesthetic agents) |
| 5. Blood gas exchange |
| ↗P A-aO2 gradient due to mismatch in regional VA/Q ratios |
| 6. Immune function |
| ↙ Bactericidal activity of alveolar and bronchial macrophages |
| ↗ Release of pro-inflammatory cytokines |
Abbreviations: PA-aO2 gradient, alveolar-arterial oxygen gradient; VA/Q ratios, ventilation – perfusion ratios.
Strategies to reduce the risk of major postoperative complications
| Clinical risk stratification | B | MI, CHF, arhythmia, operative mortality |
| Smoking cessation | ? | MIsch |
| Drugs | ||
| – Beta-adrenergic antagonists | A and B | MIsch, MI, CHF, arhythmia, short-long-term mortality |
| – Alpha2-adrenergic agonists | B | Misch, MI, short-term mortality |
| – Calcium-channel blockers | C | MI, CHF, arhythmia, short-term mortality |
| – Statines | C | MI, short-long-term mortality |
| – Aspirine | C | MI, short-long-term mortality |
| Regional analgesia | ||
| – Thoracic epidural analgesia (intra-postoperative) | B | MI (mortality) |
| – Spinal/Epidural analgesia | C | Mortality, deep venous thrombosis, PTE, (MI, stroke) |
| Rewarming, normothermia | B | Misch |
| Hematocrit > 28% | C | Misch, serious cardiac adverse events |
| Right heart catheterization | D | Mortality, arhythmia, thromboembolism |
| Clinical risk stratification | C | Atelectasis, BPN, respiratory failure |
| Smoking cessation preoperatively | I | postoperative ventilator support |
| Monitoring of neuromuscular blockade and/or short-acting myorelaxants | B | Atelectasis, BPN |
| Intraoperative neuraxial blockade vs general anesthesia | C | Mortality, BPN, respiratory failure |
| Patient-controlled vs on-demand analgesia | C | pain score, overall complication, hospital length of stay |
| Neuraxial blockade post(-intra-) operative | C | miscellaneous PPCs |
| Laparoscopic vs open procedures | C | Spirometry, atelectasis, BPN, overall PPC |
| Selective nasogastric drainage | B | Atelectasis, BPN, bronchoaspiration |
| Postoperative lung expansion modalities | B | Atelectasis, BPN, bronchitis, severe hypoxemia |
| Nutrition | ||
| – routine parenteral or enteral nutrition | D | |
| – immunonutrition | I | |
| Right heart catheterization | D | Pneumonia |
| Hand washing (medical and nursing team) | A | Wound infection |
| Antibiotic prophylaxis | A | Wound infection |
| Blood glucose control | B | Wound infection |
| Supplemental oxygen (intra-postop) | B | Wound infection |
| Rewarming, normothermia | C | Wound infection |
| Avoidance of indwelling catheters (central venous line, bladder) | C | Bacteriema, catheter-related sepsis, urinary infection |
| Smoking cessation preop | C | Wound infection |
Abbreviations: MI, myocardial infarct; Misch, myocardial ischemia; CHF, congestive heart failure; PTE, pulmonary thromboembolism; BPN, bronchopneumonia.
A = good evidence that the strategy reduces complications and that benefits outweighs harms;
B = at least fair evidence that the strategy reduces complications;
C = at least fair evidence of positive impact although the harm and benefit balance is too close to justify a general recommendation;
D = at least fair evidence that the strategy does not reduce complications or harmd outweigh benefit;
I = insufficient data.
Figure 2Progressive hyperdynamic inflation in COPD patients during mechanical ventilation and its treatment.